Stockwinners Market Radar for November 21, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:55 EST Graybug Vision, CalciMedica to merge in all-stock transaction - Graybug Vision and CalciMedica announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on further developing CalciMedica's lead product candidate Auxora, a proprietary, intravenous-formulated, small molecule calcium-release activated calcium channel inhibitor, to treat life-threatening inflammatory diseases, such as acute pancreatitis, asparaginase-associated pancreatitis, acute kidney injury, and acute hypoxemic respiratory failure, for which there are no currently approved therapies. Auxora, which modulates the immune response and protects against tissue cell injury, has been studied in four completed efficacy clinical trials, demonstrating positive and consistent clinical results, as well as a favorable safety profile. Subject to each company's stockholder approval, the combined company is expected to trade on the Nasdaq Global Market. With approximately $35M in cash and cash equivalents anticipated from the combined company, including a private placement financing expected to occur immediately prior to the merger closing, the combined company is expected to have a cash runway into the second half of 2024, funding the advancement of Auxora in AP and AAP through clinical milestones in 2023. The proposed merger is expected to close in the first quarter of 2023. Following the merger, the combined company will be headquartered in La Jolla, California and Rachel Leheny, Ph.D., will serve as Chief Executive Officer of the combined company. The merger agreement provides that the board of directors of the combined company will be composed of seven members, five selected by CalciMedica and two selected by Graybug. The merger agreement has been unanimously approved by the boards of directors of both companies and is subject to the approvals by the stockholders of each company and other customary closing conditions.

18:45 EST Graybug Vision trading halted, news pending

18:15 EST Walgreens Boots Alliance director Schlichting sells 16,750 common shares - In a regulatory filing, Walgreens Boots Alliance director Nancy Schlichting disclosed the sale of 16,750 common shares of the company on November 17 at a price of $39.887 per share.

17:46 EST Zoom Video sees Q4 deferred revenue up roughly 2%-3% y/y - Zoom Video said in prepared remarks for its Q3 earnings call that its annual seasonality of renewals is front-end loaded and moderates over the rest of the year, reflecting the sequentially smaller renewal base. As a result, the company expects Q4 deferred revenue to grow roughly 2%-3% year-over-year.

17:33 EST Integrated Rail and Resources Acquisition names Mark Michel as CEO - IRRX announced Mark Michel, current vice-chairman, president and COO, has been promoted to chairman and CEO. Timothy Fisher, current senior vice president and chief acquisitions officer, has also been promoted to vice chairman, president and CFO. Hank Didier, current vice president of investor relations, has been promoted to secretary.

17:30 EST HumanCo Acquisition Corp trading resumes

17:26 EST Electronic Arts CEO Wilson sells 10,000 common shares - In a regulatory filing, Electronic Arts CEO and board chair Andrew Wilson disclosed the sale of 10,000 common shares of the company on November 17 at a price of $128.6101 per share.

17:16 EST Bioventus issued amended Q3 results - Due to the adverse effect on the previously announced third quarter 2022 financial results and revenue guidance that resulted from additional rebate claims related to certain of the Company's products and a non-cash impairment charge required by U.S. generally accepted accounting principles resulting from the recent decline in the Company's market capitalization subsequent to its previously announced financial results for the third quarter of 2022, the Company is amending its previously announced third quarter financial results as provided below, which replaces the earnings release of November 8, 2022 in its entirety.

17:13 EST Encompass Health to build 50-bed inpatient rehab hospital in Daytona Beach - Encompass Health Corp. announced it plans to build a freestanding, 50-bed inpatient rehabilitation hospital in Daytona Beach, Florida. The hospital will be located at the southwest corner of Williamson Boulevard and Strickland Range Road. "We are excited to expand our rehabilitation services on Florida's Atlantic coast to provide much-needed rehabilitative services to individuals in the Daytona Beach area," said Lori Bedard, president of Encompass Health's Southeast region. "We remain committed to making a difference in the communities we serve by improving access to high-quality, individualized rehabilitative care, and this new hospital will allow even more residents to receive specialized care close to home."

17:10 EST ZTO Express increases share repurchase program to $1.5B - ZTO Express announced that its board of directors has approved further changes to the company's share repurchase program launched in November 2018 and adjusted in March 2021, increasing the aggregate value of shares that may be repurchased from $1B to $1.5B and extending the effective time by one year through June 30, 2024.

17:04 EST Dell Technologies says 'high degree of complexity' in current envirnoment - Says seeing some "cautiousness" with customers. Says customers purchasing for "immediate needs."

17:03 EST ZTO Express revises 2022 parcel volume growth view to 9%-11% - Taking into account the current market conditions and the uncertainties associated with macro economy and COVID-19, the company revises its previously stated annual guidance. Parcel volume for 2022 is expected to be in the range of 24.3B-24.74B, representing a 9% to 11% increase year over year. Relative to the entire industry performance, the company is confident to achieve at least one percentage point increase in its market share for the entire year. Such estimates represent management's current and preliminary view, which are subject to change.

17:03 EST Camping World COO Tamara Ward to retire - Camping World Holdings announced that Tamara Ward will retire from her position as Chief Operating Officer effective December 31, 2022. Matthew Wagner, Executive Vice President, will be promoted into the Chief Operating Officer role on January 1, 2023, as part of a planned leadership succession. Ward joined Camping World in 1989 as a marketing intern and has served a variety of executive roles over her nearly 34-year career including Chief Marketing Officer, Executive Vice President and Senior Vice President Sales and Marketing. She has been the Company's Chief Operating Officer since 2019. Ward is expected to remain with the Company through 2024 as a senior advisor to assist with the transition and provide guidance and mentorship to new organizational talent. "I am grateful to have spent over 30 years alongside many talented team members learning and helping grow the business," said Ms. Ward. "I am proud to have been a part of many accomplishments and am confident in Matt's ability to bring new opportunities and innovation into the Company. Having had the opportunity to work with Matt for many years, I fully endorse his promotion and look forward to a smooth transition and am excited for the organization's future growth."

16:53 EST Gamida Cell says FDA extends omidubicel's PDUFA date to May 1, 2023 - Gamida Cell provided an update on recent interactions with the U.S. Food and Drug Administration relating to the company's Biologics License Application for omidubicel, the company's advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant. As part of its ongoing BLA review, FDA issued an information request and viewed the data in the response as a major amendment, resulting in an extension of the omidubicel Prescription Drug User Fee Act date from January 30, 2023 to May 1, 2023. The agency also rescheduled Gamida Cell's late-cycle meeting to the first quarter of 2023. The data FDA requested were laboratory results for intermediate time points for patients enrolled in the Phase 3 study. These additional data provided by Gamida Cell to FDA are consistent with prior data submissions. "We appreciate the FDA's collaboration as they conduct their review of omidubicel," said Abigail "Abbey" Jenkins, Gamida Cell's President and Chief Executive Officer. "If approved, omidubicel will be the first and only advanced cell therapy for patients with blood cancer in need of an allogeneic stem cell transplant. We are committed to bringing this potentially transformative therapy forward as quickly as possible."

16:47 EST Horizon Global CEO Terrence Gohl resigns, John Kennedy named interim CEO - Horizon Global announced that the company's board of directors appointed John Kennedy as interim president and CEO. Kennedy will continue to serve as chair of the board. This appointment follows the board's acceptance of Terrence Gohl's resignation from his executive positions and as a director.

16:43 EST GigInternational1 Inc trading halted, news pending

16:35 EST Camping World COO Tamara Ward to retire, Matthew Wagner to succeed - On November 17, Tamara Ward, COO of Camping World Holdings, notified the company that she will retire from such role, effective as of the close of business on December 31, upon the expiration of her existing employment agreement. Also on November 17, the company's Board of Directors appointed Matthew Wagner as COO of the company, effective January 1, 2023, and the Board designated Wagner as the company's principal operating officer, effective on the Effective Date and succeeding Ward in such role. Ward is expected to remain employed with the company as a senior advisor. On or before the Transition Date, the company intends to enter into a transition agreement with Ward describing the terms of Ward's employment as a senior advisor. The company also intends to enter into an employment agreement with Wagner on or before the Transition Date describing the terms of Wagner's employment as COO.

16:32 EST Gold Royalty names Andrew Gubbels as CFO, effective January 1, 2023 - Gubbels will assume the responsibilities of CFO from Josephine Man, who will be leaving the company in 2023 to focus on other opportunities.

16:30 EST Treace Medical announces 1st patient reated in MTA3D Adductoplasty study - Treace Medical Concepts announced treatment of the first patient in the MTA3D Adductoplasty Clinical Study. The study will evaluate outcomes of the Adductoplasty Procedure combined with the Lapiplasty Procedure for patients in need of hallux valgus and metatarsus adductus correction surgery. Midfoot deformities may occur in up to 30% of hallux valgus patients.1,2 The study, "Radiographic and Patient Reported Outcomes Following Combined Adductoplasty and Lapiplasty Procedures for Correction of Metatarsus Adductus and Hallux Valgus is a prospective, multicenter, unblinded clinical study, with up to 80 patients treated in up to 10 U.S. sites. Patients in the study will be followed for 5 years. "Recurrence rates following traditional hallux valgus correction are found to be significantly higher when certain deformities of the midfoot are present.3,4 With Adductoplasty and Lapiplasty instrumentation, we now have technologies to enable reproducible correction of both the bunion and coexisting midfoot deformities," said Paul D. Dayton, DPM, MS, FACFAS of Foot & Ankle Center of Iowa and co-lead principal investigator. "With the first patient now treated, we look forward to advancing the MTA3D(TM) Clinical Study and reporting on outcomes following the procedures." Mark Easley, MD, Chief, Duke University Foot and Ankle Division, is also co-lead principal investigator

16:30 EST PacWest Bancorp CEO Matthew Wagner to switch roles, Paul Taylor to succeed - PacWest Bancorp announced the following changes to the company's board and executive team. Paul Taylor, president of the company and the bank, has been appointed CEO of the company and the bank, effective January 1. Taylor will have full management, financial, and leadership responsibilities for the company's and the bank's operations. Matthew Wagner, CEO of the company and the bank, will transition to the role of executive chairman of the boards of directors for the company and the bank for a one-year term beginning January 1, 2023. In this role, Wagner will focus on customer relations, technology development, and supporting a transition of duties to Taylor. John Eggemeyer, III, chairman of the company's board, will transition to the role of lead director, effective January 1, 2023. Kevin Thompson has been appointed executive VP, CFO, effective November 28. Thompson has more than 20 years of experience in finance and has spent more than 15 years in senior finance roles in the banking sector, including as CFO of First Foundation Inc., Opus Bank, Midland States Bancorp, and American Express Centurion Bank. He succeeds Bart Olson, who will assume the role of executive VP, finance, through February 28, 2023, to assist with an orderly transition.

16:21 EST Air Transport Services names Paul Chase chief commercial officer - Air Transport Services Group announced that Paul Chase, an experienced air cargo industry executive, will assume Mike Berger's responsibilities as Chief Commercial Officer when Berger transitions to Chief Strategy Officer, effective December 5, 2022. Chase will assume responsibility for sales, marketing strategy and execution for the ATSG family of companies. He will report to ATSG President and CEO Rich Corrado. "Paul's background includes a number of roles that relate directly to fostering new and ongoing relationships with leading companies in the markets we serve," Corrado said. "I am confident that his complementary skills will help guide ATSG's leadership team toward investments, service offerings and business relationships that leverage our experience, assets and innovative people, and extend our leadership in the midsize, dedicated aircraft markets we serve." Berger has accepted the newly created position of Chief Strategy Officer, responsible for the analysis and development of new ventures consistent with ATSG's global business strategy. Berger joined ATSG as CCO in February 2018. ATSG has had a strong focus on growing its business globally in recent years, and Berger's new role will allow for further concentration in key development areas.

16:18 EST Construction Partners acquires three hot-mix asphalt plants in Tennessee - Construction Partners announced that it has acquired three hot-mix asphalt plants in the Nashville, Tennessee metro area from Blue Water Industries. These HMA plants and the related construction operations will be integrated as a bolt-on acquisition to CPI's Alabama-based platform company, Wiregrass Construction Company, which maintains operations within close proximity to the Nashville metro area. In connection with the transaction, CPI also received cash and transferred ownership of its Daurity Springs Quarry in North Carolina to Blue Water Industries, while retaining aggregate sourcing rights from the quarry for its hot-mix asphalt plants in the central North Carolina area.

16:16 EST Norfolk Southern to purchase assets of Cincinnati Southern Railway - Norfolk Southern announced the execution of a purchase agreement under which the company's operating subsidiary, Norfolk Southern Railway Company, will acquire substantially all of the assets of the Cincinnati Southern Railway, an approximately 337 mile railroad that runs from Cincinnati, Ohio to Chattanooga, Tennessee. The CSR is currently owned by the City of Cincinnati and operated by the Cincinnati, New Orleans and Texas Pacific Railway Company, a wholly owned subsidiary of Norfolk Southern Railway, under a lease agreement expiring in 2026. The agreement provides the company ownership of approximately 9,500 acres of land that sits under infrastructure maintained and operated by Norfolk Southern. Further, it ensures Norfolk Southern will own the line in perpetuity, while eliminating uncertainty around future lease costs. The line is one of the highest density segments of the company's network, with as many as 30 trains a day traveling the route. Upon the close of the transaction, projected to occur in the first half of 2024, the City of Cincinnati will receive cash consideration of approximately $1.62B. Norfolk Southern intends to finance the transaction through a combination of internal and external sources. The City of Cincinnati plans to use the proceeds of the transaction to form an infrastructure fund that will benefit the citizens of Cincinnati for generations to come. The trust would solely fund the rehabilitation, modernization, or replacement of existing infrastructure such as streets, bridges, municipal buildings, parks, and green space. The closing is subject to certain conditions, including approval by the voters of Cincinnati and the U.S. Surface Transportation Board.

16:14 EST Hingham Institution announces 3% dividend raise of 63c per share - Hingham, Massachusetts announced that its Board of Directors has declared a regular quarterly cash dividend of 63c per share. This represents an increase of 3% over the previous regular quarterly dividend of 61c per share. The dividend will be paid on January 11, 2023 to stockholders of record as of January 2, 2023.

16:11 EST Prothena achieves $40M clinical milestone payment from Novo Nordisk - Prothena Corporation (PRTA) announced that the company has earned a $40M milestone payment from Novo Nordisk (NVO) related to the continued advancement of NNC6019 in a Phase 2 clinical study for the treatment of ATTR cardiomyopathy. There remains a high unmet medical need in moderate to advanced ATTR amyloidosis patients at high risk for early mortality due to amyloid deposition in vital organs. Under the terms of the agreement, Prothena is eligible to receive up to $1.2B upon achievement of several clinical development and sales milestones, including the $100M earned to date. Novo Nordisk gained full worldwide rights to the intellectual property and related rights of the ATTR amyloidosis business and pipeline it acquired from Prothena in July 2021.

16:09 EST ICF International awarded over $45M in digital modernization contracts by HHS - U.S. Department of Health and Human Services' Centers for Medicare & Medicaid Services recently awarded global consulting and digital services provider ICF two contracts to support CMS' digital modernization efforts to improve access to critical public health data. Both contracts were awarded in the third quarter of 2022 and will continue the work performed by SemanticBits, which was acquired by ICF earlier this year. The first contract is a $25M recompete task order to develop, operate and maintain data.cms.gov, the agency's health data sharing website, to ensure critical information can be easily discovered, accessed and used by healthcare professionals and the public. It has a term of 54 months, including a six-month base and four 12-month options. The second contract is a $20M expansion to modernize CMS' Internet Quality Improvement and Evaluation System which is used by healthcare providers and over 60 federal and state agencies to manage billions of records annually. ICF will also continue to build systems to meet Medicare survey requirements and implement new functionality to comply with federal reporting requirements. The term of the expansion is 12 months.

16:04 EST Puhui Wealth receives noncompliance notification from Nasdaq - Puhui Wealth announced that the company had received a staff determination letter on November 16 from the Listing Qualifications Department of Nasdaq Stock Market notifying the company of its noncompliance with the Nasdaq Listing Rule 5250 for continued listing due to its failure to file its Form 20-F for the fiscal year ended June 30, which serves as an additional basis for delisting the company's securities from The Nasdaq Stock Market in addition to the company's noncompliance with the Nasdaq's minimum bid price requirement under the Nasdaq Listing Rule 5550 as previously disclosed on a Form 6-K filed by the company on April 22 and October 17, respectively.

15:27 EST SoFi says cryptocurrency 'non-material component' of business - SoFi Technologies disclosed in a regulatory filing: "In response to a letter received on November 21, 2022 from four Democratic members of the Senate Banking Committee requesting information regarding the activities of SoFi Technologies, Inc. with respect to digital asset trading, the company issued the following statement: SoFi takes our regulatory and compliance commitments seriously, including our non-bank operations within the digital assets space. We believe we have been fully compliant with the mandates of our bank license and all applicable laws. We maintain consistent, constructive dialogue with each of our federal and state regulators. Cryptocurrency remains a non-material component of our business. As disclosed in our latest 10-Q filing, our brokerage related fees, which include all cryptocurrency related fees, totaled $3.85 million in the third quarter of 2022 and the fair value of digital assets held by third-party custodians for the benefit of our members, which is recorded on our consolidated balance sheet, totaled approximately $132.5 million as of September 30, 2022. We do not engage in any other cryptocurrency financing activity other than allowing members to buy and sell crypto currency via our platform executed by third party partners, including no leveraging or yielding. We do not partner with FTX nor have any direct exposure to FTX."

14:17 EST DraftKings sees no evidence that company systems were breached

14:07 EST Sen. Brown, colleagues ask bank regulators to review SoFi's crypto activities - Sen. Sherrod Brown, Chair of the Senate Committee on Banking, Housing, and Urban Affairs, and Committee members Sens. Jack Reed, Chris Van Hollen, and Tina Smith sent letters urging Federal Reserve Vice Chair for Supervision Michael Barr, FDIC Acting Chair Marty Gruenberg, and Acting Comptroller Michael Hsu to review SoFi's crypto trading activities. The lawmakers highlighted "the risk to consumers when banks trade volatile crypto assets and warned that SoFi's crypto trading may be in violation of regulatory requirements." "SoFi's digital asset activities pose significant risks to both individual investors and safety and soundness," they wrote. "...it is imperative the Fed, FDIC, and OCC ensure that SoFi complies with all consumer financial protection and banking regulations. We commend you for the work that your agencies are doing to protect the public from digital asset risks." The lawmakers also wrote a letter to SoFi's CEO Anthony Noto, pressing the bank to conform to U.S. banking law. "We are concerned that SoFi's continued impermissible digital asset activities demonstrate a failure to take seriously its regulatory commitments and to adhere to its obligations," they wrote. Reference Link

13:47 EST LCNB Corp. raises dividend 5% to 21c per share - LCNB Corp. announced that the company's board of directors declared a cash dividend of 21c per common share, which is a 5% increase over the same period last year. The common stock cash dividend will have a record date of December 1 and is payable to shareholders on December 15. Eric Meilstrup, President and CEO, stated, "I am pleased with our Board's decision to increase our quarterly dividend for the fifth consecutive year. In fact, since 1998, our dividend has increased at a compound annual growth rate of 3.4%. We will have returned a record amount of capital back to shareholders this year through our dividend and stock repurchase programs. This reflects continued strength in LCNB's operating and financial results, as well as our commitment to return capital to shareholders."

13:27 EST Pitney Bowes confirms 'ongoing dialogue with Hestia Capital over many months' - In a statement emailed to The Fly, a spokesperson for Pitney Bowes said that, "Pitney Bowes engages in open and regular communication with shareholders and welcomes constructive input on how to enhance long term shareholder value. This communication with shareholders includes an ongoing dialogue with Hestia Capital over many months. We continue to engage in good faith around Hestia's perspectives." "Our Board of Directors and management team remain focused on delivering sustainable future value for all stakeholders. We have seen investments in SendTech and Presort lead to stabilization and indeed potential for growth. As we noted in our third quarter earnings, we are seeing positive volume trends and margin growth in our Domestic Parcel network within our Global Ecommerce business. As we continue to navigate a turbulent market, we believe our businesses are very well positioned for future success." In a regulatory filing on Monday, Hestia Capital disclosed a 6.9% stake in Pitney Bowes.

12:17 EST Papa John's names Elias Reyna as chief people and diversity officer - Papa John's International announced the appointment of Elias Reyna as the company's new Chief People and Diversity Officer. Reyna, who will begin his new position on November 28, will lead globally the human resources; diversity, equity and inclusion; talent recruiting and management; total rewards; and employee relations functions, reporting to president and CEO Rob Lynch. Reyna joins Papa Johns from ABM Industries where he was Vice President Human Resources, Manufacturing and Distribution.

12:00 EST Carvana falls -14.1% - Carvana is down -14.1%, or -$1.14 to $6.92.

12:00 EST Nine Energy Service falls -27.4% - Nine Energy Service is down -27.4%, or -$2.81 to $7.46.

12:00 EST Copel rises 21.7% - Copel is up 21.7%, or $1.43 to $8.00.

11:16 EST Palm Beach Capital exits Cadre Holdings investment - Palm Beach Capital Fund III has fully exited its investment in Cadre Holdings and realized proceeds equal to 9.3 times its invested capital.

10:46 EST DraftKings slides amid reports of users being hacked - Shares of DraftKings are falling in Monday morning trading after Action Network's Darren Rovell reported on users reporting being hacked and having money in their accounts cashed out. DraftKings said via Twitter that "We are aware of reports of customers having issues with their accounts, and we are investigating... If any customers are having issues with their accounts, please contact Customer Experience Team at support@draftkings.com." A DraftKings representative acknowledged the situation on Monday morning but did not immediately comment, according to Rovell's report. In Monday morning trading, shares of DraftKings are down $1.30, or 9%, to $13.75. Reference Link

10:00 EST ProShares UltraShort Bloomberg Natural Gas falls -9.5% - ProShares UltraShort Bloomberg Natural Gas is down -9.5%, or -$1.48 to $14.03.

10:00 EST Grindr falls -10.8% - Grindr is down -10.8%, or -$3.94 to $32.55.

10:00 EST Atento rises 20.4% - Atento is up 20.4%, or $1.16 to $6.84.

09:59 EST Helbiz to reduce staff by 15%, look for Media business partner - Helbiz will undertake several measures to reduce costs going forward to lessen the financial burden of the company and shorten the path to profitability. The cost cuts and staff reduction will lower the monthly burn rate between 20 to 30%. Over the coming days, staff will be reduced in the U.S. and Europe by 15% across corporate and operations teams. As well, a deep review of current costs and obligations will be undertaken that will look to further reduce spend. Already, Helbiz has been working with third parties and slimming down operations where it makes sense to reduce cost. Lastly, Helbiz will search for partners to share or take over the operation of the Media business to reduce them as on-going cost centers and return focus entirely on mobility business. "As we reviewed the business, we concluded that our core mobility business has the best potential to quickly achieve profitable operations," said CEO and Founder Salvatore Palella. "We will return to focusing only on Mobility, with the goal of becoming the world leader in mobility. To make this happen we must change, cutting costs and divisions. To preserve our capital and get to profitability, we must take action to align our cash usage with the most likely driver of revenue growth in the quarters ahead. This cut will bring the cut burning from 20 to 30% down in the immediate future, we will also start conversations with partners regarding the Media business."

09:47 EST ProShares UltraShort Bloomberg Natural Gas falls -6.7% - ProShares UltraShort Bloomberg Natural Gas is down -6.7%, or -$1.04 to $14.47.

09:47 EST Nine Energy Service falls -7.6% - Nine Energy Service is down -7.6%, or -78c to $9.49.

09:47 EST Atento rises 19.4% - Atento is up 19.4%, or $1.10 to $6.78.

09:45 EST Iconiq Hdg Corp trading resumes

09:37 EST Sotera Health trading resumes

09:37 EST Sotera Health jumps after Sterigenics found not liable for woman's cancer - Shares of Sotera Health are up $2.59, or 43%, to $8.61 and were halted for volatility in early Monday morning trading after it was reported on Friday night that a Cook County jury ruled that medical device sterilizer Sterigenics should bear no liability for cancer in a woman who lived near Sterigenics' former Willowbrook plant. That verdict, delivered Nov. 19, came at the close of the second trial among hundreds of cases still pending against the company over its emissions of the chemical known as ethylene oxide, reported Jonathan Bilyk in the Cook County Record. Sterigenics is a defendant, along with its parent company, Ohio-based Sotera Health, and Alsip-based Griffith Foods, which had initially owned and operated the Willowbrook sterilization plant that would bear the Sterigenics name, the report noted. Reference Link

09:35 EST Iconiq Hdg Corp trading halted, volatility trading pause

09:32 EST Sotera Health trading halted, volatility trading pause

09:31 EST Atento trading halted, volatility trading pause

09:28 EST WidePoint ITMS achieves 'FedRAMP in Process' status - WidePoint Corporation announced that the company's Intelligent Technology Management System has achieved "FedRAMP in Process" status. The FedRAMP Program Management Officer updated the status for WidePoint's proprietary Intelligent Technology Management System from "FedRAMP Ready" to "FedRAMP In Process" on the FedRAMP Marketplace with the U.S. Department of Justice, Bureau of Alcohol, Tobacco, Firearms and Explosives as the sponsoring agency. WidePoint is working with a contracted Third-Party Assessment Organization and ATF to review and test the 616 security controls and sub-controls necessary to achieve FedRAMP Authorization at the FISMA moderate level. WidePoint will have six months to complete the assessment to earn a FedRAMP Authorization status. Once the FedRAMP Authorization is issued, ITMS will enter a continuous monitoring phase. WidePoint will continue to work with a 3PAO to annually review a subset of security controls, submit assessment reports to ATF, conduct penetration testing, and assess any required security control changes.

09:25 EST Hestia Capital reports 6.9% stake in Pitney Bowes, engaging in talks - Hestia Capital reports it holds a 6.9% stake in Pitney Bowes, having purchased the shares based on their belief that the shares, when purchased, "constituted an attractive investment opportunity." Hestia believes the shares are "currently undervalued and have privately engaged and continue to engage in discussions with the [company's] management and its board of directors about, among other things, enhancing the [company's] capital allocation, improving operational performance, and making changes to the board's composition," the firm stated in a regulatory filing.

09:13 EST Intuit, NFL expand official partnership in four-year renewal - The National Football League and Intuit announced it has expanded its official partnership in a four-year renewal deal through 2026. As the official financial and accounting software sponsor for the NFL since 2019, Intuit's sponsorship now includes additional brands and business categories that support its evolving business. New this year, Intuit Mailchimp is now also the official email marketing and automation sponsor for the NFL. As a part of the sponsorship, Intuit TurboTax will continue to be the presenting sponsor of both the AFC and NFC Divisional games and the AFC and NFC Championship Games for the 2022 NFL season.

09:11 EST Playtika agrees to $25M minority investment in Ace Games - Playtika announced execution of an agreement for a $25M minority investment in Turkish mobile gaming company Ace Games. Ace is the developer of Fiona's Farm, a free-to-play innovative casual mobile game that expertly and uniquely combines the mechanics of Match-3, farming, decoration, and narrative-driven games into one immersive mobile gaming experience for players. "Our investment in Ace Games is an important milestone in the execution of our new games investment strategy as Playtika continues to seek exposure to high-growth potential game IP in cost-effective ways," said Robert Antokol, Chief Executive Officer of Playtika. "The talented team at Ace has built a best-in-class and innovative product on the 'Match-3 and Meta' game model. Playtika can greatly complement Ace with our LiveOps and Digital Studio capabilities, leveraging our enhanced monetization and game operations leadership in mobile gaming."

09:08 EST EnWave announces renewal of normal course issuer bid - EnWave Corporation announced that the TSX Venture Exchange has provided conditional acceptance of the Company's normal course issuer bid, subject to the Company meeting all of the requirements of the TSXV. Under the terms of the normal course issuer bid, EnWave may acquire up to 10,798,644 common shares, representing 10% of the public float of EnWave as of November 21, 2022. In the opinion of the Company's Board of Directors, its common shares trade at prices that do not reflect the underlying value of the Company including its growing royalty portfolio, its financial position and other material commercial opportunities. Accordingly, EnWave believes that purchasing and returning its common shares to treasury, when deemed appropriate by the Company, represents an opportunity to enhance value for its ongoing shareholders. As of November 21, 2022, the Company had 110,440,055 common shares outstanding. Under TSXV policies, EnWave is entitled to purchase up to 2,208,801 shares in any 30-day period up to the maximum of 10,798,864 shares. The purchases may commence on November 24, 2022 and will end on November 23, 2023, or on such earlier date as EnWave may complete its purchases pursuant to the notice of intention to make a normal course issuer bid filed with the TSXV. The actual number of common shares which will be purchased and the timing of any such purchases will be determined by the Company. All shares purchased by the Company will be on the open market through the facilities of TSXV by Cormark Securities Inc. acting on behalf of EnWave in accordance with the policies of the TSXV and will be surrendered by the Company to its transfer agent for cancellation. The prices that EnWave will pay for any of the common shares purchased will be the market price of the shares at the time of acquisition.EnWave did not purchase or cancel any common shares under the previous normal course issuer bid that commenced on October 29, 2021 and expired on October 28, 2022.

09:05 EST United-Guardian board declares year-end dividend of 31c per share - United-Guardian announced that the company's Board of Directors, at its meeting on November 15, 2022, declared a cash dividend of 31c per share, which will be paid on December 7, 2022 to all stockholders of record on November 28, 2022.

09:05 EST Allied Esports Entertainment announces $10M stock repurchase program - Allied Esports Entertainment announced that the Company's Board of Directors has authorized a stock repurchase program of up to $10M of its outstanding shares of common stock. The manner, timing and amount of any purchase will be based on an evaluation of market conditions, stock price and other factors. "Allied Esports Entertainment is committed to maximizing shareholder value, and we feel this stock repurchase authorization is a positive step towards this goal," said Ms. Yinghua Chen, Chief Executive Officer. "We believe the current share price does not reflect the Company's intrinsic value and this action underscores the Board's confidence in the Company. Given our strong balance sheet, we believe this share repurchase program is a timely and appropriate use of the Company's capital resources." Repurchases under the program will be made in open market transactions in compliance with the Securities and Exchange Commission Rule 10b-18 and federal securities laws. The stock repurchase program is expected to be completed over the next 24 months. The stock repurchase program does not obligate the Company to acquire any particular amount of common stock, and it may be extended, suspended or discontinued at any time at the Company's discretion. The stock repurchase will be funded using the Company's working capital. Any shares purchased under this program will be returned to the status of authorized but unissued shares of common stock.

09:04 EST Great Elm Group announces board of directors updates - Great Elm announced that Jeff Serota and Tom Harbin have departed the Company's Board of Directors following the conclusion of the 2022 Annual Stockholders' Meeting. Serota and Harbin had previously decided not to stand for reelection at this year's meeting. "On behalf of Great Elm, its Board, management and shareholders, I would like to thank Jeff and Tom for their years of dedicated service and insight," said Jason Reese, Executive Chairman of GEG. "We are grateful for their many contributions to the company."

08:56 EST Apartment Income REIT sells six community New England portfolio for $500M - Apartment Income REIT announced the sale last week of its New England portfolio of six communities with 1,314 apartment units for $500M. The disposition price represents a trailing twelve-month NOI cap rate of approximately 4.4%. John McGrath, Chairman of the AIR Investment Committee, noted: "Since the end of 2020, AIR has completed $2.2B of property sales and joint venture transactions at prices averaging 17% above internal estimates of gross asset value as of Q1 2020, which were substantially identical to those prepared and published at that time by Green Street Advisors. Consistent with our paired trade philosophy and focus on accretive growth, we have enhanced our portfolio by reinvesting in approximately $1.7B of acquisitions , as well as reducing leverage. We expect additional acquisitions to increase the Acquisition Portfolio from 17% of GAV to 30%. We also expect this portfolio will earn unlevered IRRs that exceed by more than 200 basis points the consistently calculated IRRs of the properties sold to fund the acquisitions."

08:53 EST Sono Motors expands cooperation with Continental for Sion development - Sono Motors (SEV) expands its cooperation with the technology company Continental (CTTAY) by equipping the Sion series-validation vehicles, the Company's solar electric vehicle, with further proven technologies from the automotive supplier. Among other things, the companies will integrate an advanced driver assistance system from Continental in Sono Motors' series-validation vehicles for the first time, as part of the expanded cooperation. A future-proof ADAS feature is planned to be standard in every Sion, which is expected to retail for approximately EUR 25,000 net. Prospectively, the ADAS will not only make driving the Sion safer and more comfortable, but will also ensure that the Sion complies with the upcoming stricter European Union road safety regulations. The cooperation enables Sono Motors to increase efficiency in its development of the Sion, which has the potential to become the world's first affordable SEV, by using existing modern technologies. Sono Motors currently plans to start production of the Sion in the second half of 2023.

08:49 EST Apollo Endosurgery completes transition to European MDR requirements - Apollo Endosurgery announced that it has successfully transitioned its legacy products to CE Mark under the European Medical Device Regulation. The new certificates were issued by British Standards Institute and were received by the company on November 17, 2022. The certificates are valid for five years. Importantly, as part of the transition to EU MDR, the OverStitch system has a new, more specific, intended use statement in the Instructions For Use in CE-Mark countries, reading as follows: "The OverStitch Endoscopic Suture System is indicated for the endoscopic placement of anchor sutures. Anchor-sutures can be placed for defect closure, stent fixation to reduce migration rates in the upper GI tract, endoscopic sleeve gastroplasty, and transoral outlet reduction."

08:48 EST Ideanomics, A-1 Alternative Fuel to build hydrogen fuel cell electric buses - Ideanomics (IDEX) announces that its subsidiary, U.S. Hybrid, joined a consortium led by A-1 Alternative Fuel Systems, to develop hydrogen fuel cell electric shuttle buses. Supported by funding from the South Coast Air Quality Management District and SoCalGas, consortium partners will develop a zero-emission hydrogen fuel cell electric bus built on the Ford (F) E-450 chassis and a low-floor bus built on the Ford F-53 chassis. The paratransit buses will be developed in the United States at facilities in Wisconsin and Indiana. US Hybrid will provide the fuel cell and the EV propulsion system. A-1 Alternative Fuel Systems will provide the on-vehicle hydrogen fuel storage and delivery systems. A-1's fuel systems will be equipped with Luxfer Gas Cylinders Type-3 hydrogen tanks made with modern materials rated and suited for use at 120 degrees Celsius. The buses will be ALTOONA tested as well as EPA and CARB certified. Once complete, the two hydrogen-powered buses will enter service for a 12-month demonstration period operated by a California public transit authority. Once the demonstration is complete, the buses will be commercially available for purchase from A-1 Alternative Fuel System's nationwide bus dealer network in the second half of 2023.

08:44 EST Diana Shipping announces time charter contract for m/v Myrsini - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Salanc Pte. Ltd., for one of its Kamsarmax dry bulk vessels, the m/v Myrsini. The gross charter rate is US$15,000 per day, minus a 5% commission paid to third parties, for a period until minimum April 20, 2024 up to maximum June 28, 2024. The charter is expected to commence tomorrow. The "Myrsini" is a 82,117 dwt Kamsarmax dry bulk vessel built in 2010. The employment of "Myrsini" is anticipated to generate approximately US$7.62 million of gross revenue for the minimum scheduled period of the time charter.

08:42 EST Jaguar Health hosts symposium on managemen of cancer therapy-related diarrhea - Jaguar Health and its wholly owned subsidiary Napo Pharmaceuticals announced that Napo hosted a hybrid symposium on November 18, 2022 titled Management of Cancer Therapy-related Diarrhea: Is it time for a paradigm shift? The symposium featured presentations by leading oncology and infectious disease experts and discussed the impact of cancer therapy-related diarrhea as well as the unmet need of CTD burden based on current management guidelines. The symposium also discussed the need for prophylaxis of diarrhea in cancer patients as a paradigm-shift to mitigate the impact of CTD on activities of daily living, cancer therapy dose reductions, and/or discontinuations and overall improvement in the quality of life of cancer patients receiving targeted therapy with or without standard chemotherapy. Additionally, the panel discussed the recently published results of a recent prophylactic study in breast cancer patients receiving trastuzumab, pertuzumab and a taxane with or without crofelemer and the features of the ongoing phase 3 pivotal clinical study evaluating the safety and efficacy of crofelemer as prophylaxis for CTD in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy. The symposium was attended in-person by some of the investigators in the OnTarget study as well as remotely by investigators from various clinical sites within and outside the United States.

08:40 EST Capital Returns responds to Argo Group's investor presentation - Capital Returns Management, one of the largest shareholders among actively managed funds of Argo Group, responded to the investor presentation released by Argo's Board of Directors last week. Capital Returns had the following reaction: "To hear the story from Argo's Board, all is well and getting better at Argo. Shareholders should be forgiven if, after reading through Argo's investor presentation, they are inclined to reboot their Bloomberg terminal to ensure the stock quotes and charts are correct. The reality, for anyone with a functioning Bloomberg terminal, is quite different than the Board portrays it. There is no objective evidence that things are well at Argo. The stock is down 54% this year and the disastrous strategic decisions and performance of this company have led to $1 billion of losses for shareholders since the beginning of this year. The company has underperformed its self-selected peer group on a total returns basis this year and the last one, two, three, four, five, six, seven, eight, nine and ten years; during the tenure of every sitting director; during the tenure of the current CEO, the last CEO and Mr. Watson (three CEOs ago); during the tenure of the current CFO; since the announcement of the strategic review process and nearly any other relevant period. (And while Argo ballyhoos a recent 68-day period in which its stock outperformed the peers, we, at least, are focused on the creation of sustainable, long-term value. Of that, there is none.) The company remains undervalued, with investors assigning a value less than book value to the company and its net assets. This suggests that despite all the talk from this Board about transformation and future opportunity, shareholders have concluded that further value will likely be destroyed. A dollar in the hands of this company and Board is, according to our Bloomberg terminal, now worth just $0.78. This Board - though seemingly unable to successfully complete even simple tasks like filing a 10-K on time (twice late in consecutive years) or ensuring Argo has appropriate reserves for losses (having incurred surprise and adverse loss reserve expenses in 13 of the last 14 quarters) - would have shareholders believe that absolutely no change is needed. Shareholders, down $1 billion in the last eleven months, are being urged by this Board to sit passively and allow the incumbent directors to continue their stewardship uninterrupted. Color us skeptical. The Board's self-serving recommendation does not seem like a good one to us. We think adding two new objective, sophisticated directors to this Board is very likely to help and certainly cannot hurt. With a dollar at Argo worth only seventy-eight cents, we are inclined to believe some change is needed. We also do not believe that Mr. Plants, who was added to the Board recently and who heads the Strategic Review Committee, is a substitute for our candidates. To be very clear, we have enormous respect for Mr. Plants and welcome his participation on the Board. But public market shareholders may not be perfectly aligned with him. We understand that Argo was the largest investment ever made by Mr. Plants. He did laudable and important research undercovering the rotten core of Argo. But now Mr. Plants has a problem. His position is down significantly (FactSet estimates that he and his limited partners have a cost basis of $56 per share), and if he were to approve a sale of Argo today - even at a 50% premium (~$40 per share) - he would crystalize those substantial losses, significantly impacting his partners, fund and business. In other words, Mr. Plants has a strong incentive to oppose the sale of the company. And so, Mr. Plants may not be the best leader for the strategic review. His commercial needs, hope and interest, we fear, are in a chimeric rise from the ashes for Argo. We do not think most shareholders want to bet on such an improbable future. We encourage shareholders to check their Bloomberg terminals and vote for modest change to help increase the odds that Argo truly enters a new era and objectively considers a sale."

08:39 EST Cellectar announces presentation of preclinical data on CLR 12120 series - Cellectar Biosciences announced the presentation of preclinical data at the 13th Annual World ADC Conference supporting development of CLR 12120 series of targeted alpha therapies, TATs. The data demonstrate the versatility of the phospholipid ether, PLE, targeting platform and highlight the potential of the company's alpha emitting precision medicines. The presentation entitled: "Novel Conjugates - Radiotherapies," given by Cellectar's Chief Operating Officer, Jarrod Longcor, reports data from multiple preclinical studies of the CLR 12120 series, a series of TAT drug candidates designed to target and deliver either actinium-225, lead-212, or astatine-211 to cancer cells. Results demonstrated high tumor delivery with low off-target uptake of the CLR 12120 compounds when administered as monotherapies. Further, the mouse model data showed therapeutic efficacy of all three CLR 12120 candidates at both single and multiple doses in preclinical pancreatic and triple negative breast cancer xenograft models. James Caruso, president and CEO of Cellectar added, "We believe the PLE platform is one of the most versatile targeted cancer delivery platforms with the potential to similarly deliver various payloads to both solid and liquid tumors. To support future clinical development and partnering activities we have established a broad U.S. and international intellectual property rights portfolio around our PLE technology providing the company with freedom to operate across a broad range of treatment modalities."

08:37 EST Newtek receives approval from Federal Reserve to become bank holding company - Newtek Business Services announced that it has received approval from the Federal Reserve to become a bank holding company and a financial holding company by acquiring the National Bank of New York City, NBNYC. The pending acquisition of NBNYC remains subject to the approval of the Office of the Comptroller of the Currency, which approval is currently anticipated in the coming weeks. The approval of the Federal Reserve is conditioned on the representations and commitments made by Newtek in connection with its applications, including the discontinuance of Newtek's election to be regulated under the Investment Company Act of 1940 and to divest activities of certain of Newtek's technology portfolio companies within two years of becoming a bank holding company. Barry Sloane, Chairman, President and Chief Executive Officer said, "We are thrilled to have received the approval of the Federal Reserve to become a bank holding company and a financial holding company upon the close of the acquisition of NBNYC. While we await and anticipate approval from the OCC to acquire NBNYC, which we are hopeful to obtain shortly, we will continue to prepare and anticipate closing the acquisition in January 2023. Once we receive the remaining regulatory approval, we anticipate providing certain guidance on forecasted earnings as a bank holding company."

08:36 EST Computer Task Group announces Wauthier, SVP of Europe, stepping down - CTG announced Renald Wauthier, Senior Vice President, SVP, of Europe, is immediately stepping down from his position. The Company has appointed Bob Daelman, the current Vice President of Belgium and the United Kingdom and Managing Director of Belgium, as his successor. Bob Daelman succeeds Wauthier and assumes the Senior Vice President of European Operations position, effective immediately. He has over 30 years of technology and IT solutions and services experience, including over 20 years at CTG in increasingly responsible sales and leadership roles. As Senior Vice President, Daelman assumes executive responsibility for the strategic and operational leadership of CTG's European operations and will continue in his capacity as Managing Director of Belgium.

08:35 EST FDA clears Legend Biotech's IND application for LB2102 to treat extensive NSLC - Legend Biotech announced that the U.S. Food and Drug Administration has cleared Legend Biotech's Investigational New Drug application to proceed with the clinical development of LB2102, an investigational, autologous chimeric antigen receptor T-cell therapy for the treatment of adult patients with extensive stage small cell lung cancer. LB2102 is designed to selectively target delta-like ligand 3 , a ligand that is highly restricted to various malignancies, including SCLC, large cell neuroendocrine carcinoma , certain other neuroendocrine tumors and some prostate cancers. DLL-3 has also been linked to tumor growth, migration and invasion. The Phase 1, first-in-human, open-label clinical study is designed to evaluate the safety and preliminary efficacy of LB2102 in subjects with extensive stage SCLC and patients with LCNEC, as well as to determine the recommended dose for Phase 2. "Lung cancer is a debilitating disease that often spreads quickly. On average, only seven percent of patients with SCLC are alive five years after receiving their diagnosis," said Lida Pacaud, M.D., Vice-President of Clinical Development at Legend Biotech. "We are eagerly awaiting the start of this Phase 1 trial, and we hope that the study will provide much needed insight into the potential of this investigational CAR-T therapy."

08:34 EST Phunware appoints Russ Buyse as CEO - Phunware announcedthat Russ Buyse has been hired as the Company's CEO, effective December 28, 2022. Most recently, Russ served as COO of GlobaliD, a digital identity platform.

08:32 EST The Very Good Food Company announces U.S. retail expansion - The Very Good Food Company is pleased to announce that the company's The Very Good Butchers brand products are now available at 107 Wegmans Food Markets stores in the United States. Additionally, Very Good has expanded its product placements at existing retailers including Save-On-Foods, Farm Boy, and The Giant Company, adding over 3,000 points of distribution for the company's brand across North America.

08:20 EST Masimo publishes Masimo SET pulse oximetry peer-reviewed study - Masimo announced the publication of a peer-reviewed study regarding Masimo SET pulse oximetry performance in varying skin pigmentation in the Journal of Clinical Monitoring and Computing. The retrospective trial, "Racial effects on Masimo pulse oximetry: a laboratory study," by Drs. Steven J. Barker and Wilson C. Wilson, found that there was no clinically significant difference in the accuracy or bias between Black and White subjects studied with Masimo SET pulse oximetry and Masimo RD SET sensors. For this newly published study Barker and Wilson performed a retrospective analysis of Masimo laboratory data obtained from self-identified Black and White volunteer subjects, to evaluate differences in Masimo pulse oximeter accuracy and bias on the basis of skin tone. The investigators reviewed data collected between October 2015 and July 2021, which included 7,183 paired samples collected from 75 subjects, who were screened with the same criteria to remove potential bias based on health conditions. All subjects were exposed to the same hypoxia protocol, which varied the arterial saturation of hemoglobin between 70% and 100%. Noninvasive oxygen saturation values were obtained from Masimo SET pulse oximeters with RD SET sensors and time-matched with simultaneously taken arterial blood gas samples analyzed using an ABL-835 blood gas analyzer. The data were analyzed to determine the bias, precision, and accuracy for both groups. A negative bias of 0.20% was found for Black subjects, compared to 0.05% for White subjects. This difference of 0.15% is not clinically significant and the values are numerically indistinguishable because the SpO2 display resolution is 1% on commercially available pulse oximeters. The investigators also found a precision of 1.40% for Black subjects and 1.35% for White subjects. Accuracy was 1.42% for Black subjects and 1.35% for White subjects. These results are consistent with the accuracy specifications of RD SET sensors, which are twice as good as the current FDA clearance thresholds for medical-grade pulse oximeters.

08:20 EST Reunion Gold appoints Rick Howes as president, CEO - The board of directors of Reunion Gold (RGDFF)a nnounced that Richard Howes will be appointed to the position of President and CEO of the Company effective January 1, 2023. Rick is a mining engineer with over 39 years of experience in the mining industry, most recently as CEO of Dundee Precious Metals (DPMLF). Mr. Howes is expected to be appointed as a director of Reunion Gold at the Company's next board meeting. The Company is also announcing that Carlos Bertoni, Interim CEO, will be retiring from the management team effective January 1, 2023. Carlos will continue to work with the Company in an advisory capacity.

08:17 EST SAB Biotherapeutics initiates IND-enabling GLP toxicology study for SAB-142 - SAB Biotherapeutics announced SAB-142 is being progressed as a therapeutic agent to prevent and/or delay onset and progression of Type 1 diabetes and potentially other T-cell mediated autoimmune diseases. In an IND-enabling GLP study, SAB-142 will be compared to an FDA-approved T-cell depleting therapeutic, to assess toxicity and pharmacodynamic effects. "Type 1 diabetes is an autoimmune disease that represents a staggering unmet patient need," said Alexandra Kropotova, MD, Chief Medical Officer of SAB Biotherapeutics. "Patients in the Americas are disproportionally affected by Type 1 diabetes. From 1990 to 2019, the death rate increased in the Americas by 13.5%, in contrast to a decreasing global rate of -9.3%. The initiation of this study supports the progression of our SAB-142 immunotherapeutic towards IND filing. As such, we are aiming toward a successful IND submission for this novel immunotherapy that can positively impact the health of millions of patients with Type 1 diabetes across the globe." In the GLP toxicology study, conducted in an appropriate model, SAB-142 will be dosed at 1, 5, and 10 mg/kg and commercially available anti-thymocyte globulin will be dosed at 5 mg/kg. The study is expected to be completed in the first quarter of 2023.

08:15 EST Alignment Healthcare partners with American Diabetes Association - Alignment Health Plan and the American Diabetes Association have renewed their partnership to educate and empower the Alignment community with tools and resources for diabetes self-management. According to the ADA, nearly 15.9 million seniors 65 and older in the United States have diabetes. For those living with the disease, nutrition and activity can play an important role in staying healthy. Through this year-long agreement, Alignment is demonstrating its commitment to help people make the right food choices by sponsoring a series of virtual cooking classes to help people learn to cook healthy, budget-friendly meals. Alignment and the ADA kicked off their first of four classes - free and open to the public - with Homemade in October and will continue into the first quarter of 2023.

08:14 EST FDA accepsts BLA for Genmab's epcoritamab for LBCL treatment - Genmab announced that the U.S. Food and Drug Administration has accepted for Priority Review the Biologics License Application for subcutaneous epcoritamab an investigational bispecific antibody, for the treatment of patients with relapsed/refractory large B-cell lymphoma after two or more lines of systemic therapy. Under the Prescription Drug User Fee Act , the FDA has set a target action date of May 21, 2023. The BLA submission is based on safety and preliminary efficacy data from the LBCL cohort of the pivotal NHL-1 open-label, multi-center phase 2 clinical trial evaluating epcoritamab in patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin lymphoma . These results were presented in a late-breaking oral presentation as a part of the Presidential Symposium at the 27th Annual Meeting of the European Hematology Association in Vienna, Austria. "We are pleased that the BLA for epcoritamab has been accepted for Priority Review by the FDA, accelerating the pathway for approval and bringing us one step closer to potentially delivering a novel treatment option to relapsed and refractory LBCL patients who are in need of additional treatment options," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. "Together with our partner, AbbVie, we recognize the unmet need for safe, effective and accessible treatments for patients with B-cell malignancies and we believe that epcoritamab has the potential to become a core therapy in this patient population."

08:10 EST 3M announces reseller agreement with Rad AI - 3M Health Information Systems and Rad AI announced a strategic sales partnership in which 3M will resell Rad AI's Continuity incidental findings management and Omni impression generation solutions as a value-add to customers using 3MTM M*Modal Fluency for Imaging solution.

08:09 EST Citius Pharmaceuticals secures $3.6M through NJEDA - Citius Pharmaceuticals announced that the company has been selected to participate in New Jersey's Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss Program, and will receive $3.6M in non-dilutive capital through the New Jersey Economic Development Authority. Citius expects to receive the funds by late 2022 or early 2023.

08:09 EST Zebra Technologies namesTami Froese Chief Supply Chain Officer - Tami Froese is Zebra Technologies' new Chief Supply Chain Officer. "We are very pleased to have Tami join our executive team as Chief Supply Chain Officer," said Anders Gustafsson, Chief Executive Officer, Zebra Technologies. "Tami has been successful in the acting role over the past few months, and she has been instrumental in initiating meaningful actions to improve our supply chain. We are pleased to fill this critical position with internal talent as we continue to prioritize building a strong, inclusive culture with high-performing talent."

08:07 EST BioLife Solutions provides update on intellectual property estate - BioLife Solutions provided an update on the expansion of its intellectual property estate. During 2022, the company received notice of the granting of 7 patents by the USPTO and other patent authorities outside the United States. BioLife also filed 43 new applications for novel inventions related to its cell processing , media, storage containers, and freezers and thaw systems platforms. Several are specific to BioLife's proprietary Stirling engine technologies.

08:06 EST Rhythm announce Health Canada accepted NDS for setmelanotide - Rhythm announced that Health Canada has accepted for review its New Drug Submission, NDS, for setmelanotide, indicated in adults and pediatric patients 6 years of age and older with impairments in the MC4R pathway due to genetic diseases, for the treatment of obesity and control of hunger in BBS or biallelic pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency. Health Canada granted Priority Review of the NDS, which shortens the submission review performance target to 180 days, in comparison to 300 days for non-priority review. "We are pleased that Health Canada has accepted our NDS and look forward to working closely with the agency throughout the review process," said Carol Stiff, Rhythm's General Manager, Canada. "We are now establishing business operations in Canada, leveraging our international resources and the robust foundation we have built in the United States and Europe to inform our future potential launch."

08:05 EST Rhythm announces IMCIVREE granted marketing authorization in Great Britain - Rhythm Pharmaceuticals announced that Great Britain's Medicines & Healthcare products Regulatory Agency has expanded the marketing authorization for IMCIVREE to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome, BBS, in adult and pediatric patients 6 years of age and older. "Authorization in Great Britain for BBS is a significant milestone on the path toward delivering IMCIVREE globally to treat rare MC4R pathway-related obesities," said Yann Mazabraud, Executive Vice President, Head of International at Rhythm Pharmaceuticals. "Based on the early reception to our BBS launch in the United States and European Union, it's clear that BBS patients and their families have been waiting for a precision medicine that can effectively address both hyperphagia and severe obesity. We look forward to building on our ongoing momentum as we work with health care authorities and prepare to deliver our precision therapy to patients living in Great Britain and advance our country-by-country strategy to achieve broader market access for IMCIVREE." IMCIVREE was selected for evaluation as a "Highly Specialised Technology" by the National Institute for Health and Care Excellence. The Company plans to work closely with the United Kingdom's National Health Service to finalize guidance for coverage of IMCIVREE.

08:04 EST Applied Digital launches independent fund to acquire distressed crypto assets - Applied Digital has launched an independent fund aimed at acquiring distressed cryptocurrency assets, which may include mining hardware and digital infrastructure assets. The fund and any acquired assets will be managed by a newly formed entity, Highland Digital, which is a 50/50 joint venture between Applied Digital and GMR Limited. The independent fund is targeting raising capital of up to $100 million from outside investors. Applied Digital does not anticipate issuing any equity to raise capital for the fund, nor does it plan on directly owning any mining hardware. The new fund combines Applied Digital's digital infrastructure assets and GMR's experience of managing mining hardware through cryptocurrency market cycles to take advantage of the current distressed environment. GMR is a current customer of Applied Digital.

08:03 EST Campbell Soup announces 12-year virtual renewable power purchase agreement - Campbell Soup announced a 12-year virtual renewable power purchase agreement, supporting Campbell's goals to reduce greenhouse gas emissions. Through the agreement Campbell will purchase the electricity and the associated renewable energy credits from a 115 megawatt share of Enel's Seven Cowboy wind project in Oklahoma. The contract is expected to commence in July 2023.

08:02 EST TransAct Technologies receives $10M in orders from slot machine provider - TransAct Technologies announced that it has received orders for more than $10M from a global slot machine provider for TransAct's Epic Edge casino printer. These orders, which is expected to be delivered over the first three quarters of 2023, represents an approximately 300% increase in volume for this single global customer over the same period in 2022.

08:02 EST Kingsway Financial acquires Secure Nursing Service for $10.9M - Kingsway Financial Services announced the acquisition of the privately-held company Secure Nursing Service, the third such acquisition completed under the Kingsway Search Xcelerator Program. SNS, based in Los Angeles, California, employs highly skilled and professional per diem and travel Registered Nurses, Licensed Vocational Nurses, Certified Nurse Assistants and Allied Healthcare Professionals with multiple years of acute care hospital experience. SNS places these healthcare professionals in both per diem assignments, and in short-term and long-term travel assignments in a variety of hospitals in southern California. The transaction was structured as a purchase of SNS' assets and assumption of certain liabilities. The purchase price was $10.9M at close. The closing purchase price was financed with a combination of debt financing provided by Signature Bank and cash on hand. Pegasus Acquirer Holdings LLC and Pegasus Acquirer LLC, subsidiaries of Kingsway, borrowed a total of $6.5M, in the form of a term loan, and established a $1M revolver that was undrawn at close. The Loan has a variable interest rate equal to the Prime Rate plus 0.50%, with a floor of 5.00%. The Loan requires monthly principal and interest payments, and the term loan matures on November 18, 2028. Even after taking into consideration the anticipated effects of purchase accounting, Kingsway expects the acquisition to be immediately accretive.

07:55 EST Crypto names down in pre-market as bitcoin falls to one-week low - Stocks levered to bitcoin prices are down in pre-market trading as the cryptocurrency had briefly fallen below $16,000 overnight - its lowest level in about a week. Bit Digital (BTBT) is down 2% at 98c per share, Riot Blockchain (RIOT) is down 4% at $4.27, Marathon Digital (MARA) is down 5% at $7.09, MicroStrategy (MSTR) is down 4% at $163.90 and Coinbase Global (COIN) is down 6.5% at $42.30.

07:43 EST Biotricity surpasses $10M in annual revenue run rate - Biotricity announced it has surpassed $10M in annual revenue run rate. "With strong revenue growth each quarter, our scale and market reach increases every day," says Biotricity founder and CEO, Waqaas Al-Siddiq. "I am committed to continuing to drive growth and realize our potential. Our focus remains on providing the cardiac health market with disruptive, superior digital and AI technology at competitive pricing with unrivaled support to our customers and physician partnerships."

07:37 EST Advanced Drainage says TXDOT approves thermoplastic pipe in storm sewer - Advanced Drainage Systems announced that the Texas Department of Transportation, TXDOT, released a new special specification that approves the use of thermoplastic pipe in storm sewer and culvert applications statewide. -

07:35 EST First Foundation announces CEO Scott Kavanaugh named president - First Foundation announced that Chief Executive Officer, Scott F. Kavanaugh, has been named President of First Foundation . and First Foundation Bank, effective immediately. Chief Financial Officer and Interim President, Kevin Thompson, has stepped down. Amy Djou, First Foundation Bank's Chief Accounting Officer, will assume the position of Interim Chief Financial Officer of First Foundation Inc. and First Foundation Bank while First Foundation conducts a comprehensive search for a permanent replacement.

07:34 EST Domino's Pizza to roll out nationwide fleet of 800 Chevy Bolt EVs - Domino's Pizza (DPZ) is electrifying pizza delivery! More than 100 custom-branded 2023 Chevy Bolt electric vehicles are arriving at select franchise and corporate stores throughout the U.S. this month, with an additional 700 rolling out in the coming months, making it the largest electric pizza delivery fleet in the country. "We're excited that Domino's has chosen the Chevrolet Bolt EV to build their electric pizza delivery fleet in the U.S.," said Ed Peper, vice president of GM (GM) Fleet. "Both companies are committed to bettering our environment. GM plans to eliminate tailpipe emissions from new U.S. light duty vehicles by 2035. With an affordable price, fun driving characteristics, and a 259-mile range, the Chevy Bolt EV is the future of Domino's electrified deliveries."

07:33 EST FTI Consulting launches corporate finance, restructuring segment in Quebec - FTI Consulting announced the launch of the firm's Corporate Finance & Restructuring segment in Quebec with the appointment of Martin Franco as a Senior Managing Director in Montreal. The addition of the Corporate Finance & Restructuring segment in Quebec expands the firm's existing capabilities in the market, which include forensic and litigation consulting services. Franco has served as a monitor under the Companies' Creditors Arrangement Act, as a receiver and trustee under the Bankruptcy and Insolvency Act, as a consultant to debtors and as a consultant to banks in the analysis of operations and financial projections. The company said, "Establishing the Corporate Finance & Restructuring segment in Quebec provides clients extensive turnaround and restructuring expertise in Canada with coverage across the country, including Vancouver, Calgary, Toronto and now Montreal. Mr. Franco will focus on expanding FTI Consulting's restructuring capabilities in Quebec while helping corporations, boards, private equity sponsors, creditor constituencies and other stakeholders navigate challenges arising from liquidity problems, disruption and underperformance."

07:25 EST Ivanhoe Electric appoints Jordan Neeser as CFO - Ivanhoe Electric Executive Chairman Robert Friedland and President and CEO Taylor Melvin are pleased to announce key additions to Ivanhoe Electric's senior management team. Long serving external counsel Quentin Markin will come in-house as Executive Vice-President, Business Development and Strategy Execution, while Jordan Neeser will join as the Company's CFO. Concurrent with the addition of Mr. Markin and Mr. Neeser, several existing members of Ivanhoe Electric's management team will be assuming new roles. Catherine Barone, current Interim CFO, remains with the Company as Senior Vice-President, Finance. Graham Boyd, current Vice-President, U.S. Projects, will be elevated to Senior Vice-President, U.S. Projects. Glen Kuntz, current Chief Technical and Innovation Officer, will become Senior Vice-President, Mine Development, where he will lead the Company's efforts to advance its exploration projects through the development stage. These changes follow the recent announcement of Taylor Melvin's appointment as President and CEO and former President Eric Finlayson assuming the role of Chief of Global Exploration. All appointments and changes are effective today, except Mr. Markin, who will join the Company on January 1, 2023.

07:20 EST NeoGenomics presents new data on RaDaR Assay across early breast cancer - NeoGenomics and its liquid biopsy-focused subsidiary, Inivata, announced that new data, being presented at the 45th Annual San Antonio Breast Cancer Symposium taking place on December 6-10, support the use of the RaDaR Assay across all types of early breast cancer in both the adjuvant and surveillance settings. RaDaR is a personalized, highly-sensitive sequencing test for the detection of minimal residual disease and recurrence. MRD is the trace amounts of circulating tumor DNA that remain after surgery or other cancer treatment. One study being presented is the c-TRAK TN trial, which compared the use of RaDaR to digital PCR in the surveillance setting in 161 patients with early-stage triple negative breast cancer. Among ctDNA-positive patients, more than half were first detected by RaDaR versus 5.2% by dPCR. The use of RaDaR also was associated with a longer time between ctDNA detection and relapse. The c-TRAK TN study was selected as a spotlight poster presentation and is being presented on December 7. Data presented in poster will be updated with analysis of additional patients from the study cohort. The second study includes preliminary data from a long-term prospective cohort study called TRACER, investigating the use of RaDaR in patients with early breast cancer across multiple subtypes. Samples were measured at baseline, during neoadjuvant chemotherapy, during surgery, and during post-surgical follow up. Among the first 43 of 145 patients enrolled, RaDaR was highly sensitive, detecting ctDNA in 88% of patients prior to them receiving neoadjuvant therapy and allowing for monitoring ctDNA dynamics during treatment and surgical periods as well as identifying patients with persistent ctDNA after receiving curative-intent therapy. During neoadjuvant therapy, the majority of patients experienced a rapid decline in ctDNA levels from baseline to cycles 4 or 5. In the surgical period, 94% of patients with available specimens prior to surgery and 96% with available samples post-surgery demonstrated ctDNA clearance.

07:16 EST Charge Enterprises, BWCUMC enter charging station agreement - Charge Enterprises announced that its portfolio company Charge Infrastructure and the Baltimore-Washington Conference of The United Methodist Church signed an agreement for the strategy and development of EV charging stations and related services. Charge will work as the preferred provider to evaluate the prospect of EV charging stations for the over 600 churches represented by the BWCUMC. Charge will provide seamless EV charging infrastructure strategy, charging installation, and engineering solutions to any member church, and on-going monitoring and maintenance services. Charge will help BWCUMC execute on their goal to better serve their communities and their members with forward-looking and sustainable technology. Under the agreement, the member churches will earn revenue from the public-facing chargers. Charge and the BWCUMC will explore arrangements that allow the chargers to be installed at no cost to the congregations.

07:12 EST Akoustis joins Wi-Fi NOW industry association as Official RF Filter Partner - Akoustis Technologies announced that it has joined the Wi-Fi NOW industry association as an Official RF Filter Partner. Wi-Fi NOW supports more than 50 industry-leading partners, conducts multiple in-person Wi-Fi World Congress events every year, and supports the broader Wi-Fi industry with weekly thought-leadership information services, including online events and news. Dave Aichele, EVP of Business Development of Akoustis, stated, "The Wi-Fi NOW organization is one of the leading voices in the promotion and support of Wi-Fi technologies around the world, and Akoustis is pleased to join as an Official RF Filter Partner." Mr. Aichele continued, "We are pleased to add our voice to the association as we continue to make significant strides with our leading XBAW technology in the Wi-Fi 6E and emerging Wi-Fi 7 standards."

07:10 EST TuSimple says unable to file quarterly report on Form 10-Q - TuSimple announced that as previously disclosed in the TuSimple Holdings Notification of Late Filing on Form 12b-25, filed with the SEC on November 15, the company has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, by the prescribed due date because the company requires additional time to finalize the Form 10-Q in light of the changes to the company's board of directors and CEO on November 10, as disclosed on the company's Form 8-K filed with the SEC on the same date. While the company can provide no assurances as to timing, the company plans to file the Form 10-Q as soon as practicably possible to regain compliance with the Listing Rule.

07:09 EST PubMatic enters SPO partnership with PubMatic - Horizon Media announced a supply path optimization, SPO, partnership with PubMatic. Buying premium media inventory has become increasingly complex across formats and devices, with new challenges in targeting fragmented audiences. Partnering with PubMatic will add value to Horizon Media clients' direct, transparent, and simplified access to high-value audiences and premium inventory, including CTV, at unprecedented scale. Through the partnership, Horizon Media and PubMatic will collaborate on next-generation solutions to provide automated bid optimization using bespoke advertiser-level performance signals. "Horizon Media is a great partner in driving efficiency, transparency, and innovation to enable the development of digital advertising and its benefits for brands, publishers, and consumers," said Kyle Dozeman, Chief Revenue Officer, Americas, at PubMatic. "Their media buying scope combined with our omnichannel quality and scale provides one of the most robust media opportunities on the open internet for both brands and publishers. We're looking forward to delivering more custom capabilities that further improve the media buying process, deliver deeper insights, and ultimately create more value."

07:07 EST Castle Biosciences gets ccreditation from College of American Pathology - Castle Biosciences announced that the Accreditation Committee of the College of American Pathologists has accredited its clinical laboratory facility in Pittsburgh. This achievement follows a recent on-site inspection as part of the CAP's Laboratory Accreditation Program. "This important accreditation is reflective of Castle's commitment to excellence, safety and quality, driven by our dedicated laboratory team," said Kristen Oelschlager, chief operating officer of Castle Biosciences. "We are proud that clinicians and patients can use our innovative tests knowing that our clinical laboratories have received this accreditation reserved for laboratories operating under the high standards required by CAP."

07:06 EST Concert Pharmaceuticals presents data from THRIVE-AA1 study - Concert Pharmaceuticals announced the presentation of data from its THRIVE-AA1 Phase 3 clinical trial during the 12th World Congress for Hair Research. The presentation highlights THRIVE-AA1 study results evaluating Concert's investigational oral medicine deuruxolitinib in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss. The World Congress presentation includes new analyses from THRIVE-AA1 showing the effect of deuruxolitinib on regrowth of scalp hair based on disease severity and duration of current episode of hair loss. The data are being presented by Brett King, Department of Dermatology, Yale University School of Medicine and clinical investigator of THRIVE-AA1. In THRIVE-AA1, significant improvements in scalp hair regrowth compared to placebo were achieved at 24 weeks for patients taking 8 mg twice-daily and 12 mg twice-daily doses of deuruxolitinib, as previously disclosed in the positive topline results reported by Concert earlier this year. Treatment with deuruxolitinib was generally well tolerated. The newly presented analyses on disease severity and duration of current episode of hair loss from THRIVE-AA1 include: For patients with an absolute Severity of Alopecia Tool, or SALT, score less than 95 at baseline, 43% and 57% of the 8 mg twice-daily and 12 mg twice-daily deuruxolitinib dose groups, respectively, achieved a SALT score of 20 or less at Week 24, compared to 1% of patients in the placebo group. The onset of effect was significant as early as Week 8 for both doses. For patients with a SALT score greater than or equal to 95 at baseline, 20% and 30% of the 8 mg twice-daily and 12 mg twice-daily deuruxolitinib dose groups, respectively, achieved a SALT score of 20 or less at Week 24, compared to 0% of patients in the placebo group. The onset of effect was significant as early as Week 12 for both doses. For patients whose duration of current episode of hair loss was less than four years, the proportion of patients achieving a SALT score of 20 or less by Week 24 was 33% and 48% in the deuruxolitinib 8 mg twice-daily and 12 mg twice-daily dose groups, respectively, compared to 1% of patients in the placebo group. For patients whose duration of current episode of hair loss was greater than or equal to four years, the proportion of patients achieving a SALT score of 20 or less by Week 24 was 23% and 29% in the deuruxolitinib 8 mg twice-daily and 12 mg twice-daily dose groups, respectively, compared to 0% of patients in the placebo group. Deuruxolitinib was generally well-tolerated in THRIVE-AA1, consistent with its other Phase 2 and Phase 3 studies. The most common side effects in any dose group were headache, acne, upper respiratory infection, increased creatine kinase levels, COVID-19 infection and nasopharyngitis. Upper respiratory infections were greater in the placebo group than in either of the deuruxolitinib dose groups. No pulmonary embolisms or deep vein thromboses were observed in the trial. One patient treated with the 8 mg twice-daily dose and one patient treated with the 12 mg twice-daily dose developed herpes zoster. Serious adverse events were reported in nine patients, with only one patient having events that were assessed as possibly related to treatment. Four patients who reported serious adverse events were in the placebo group.

07:05 EST Pixelworks expands collaboration with MediaTek - Pixelworks recently announced that MediaTek has adopted the company's visual processing Pro Software solution in its new Dimensity 9200 5G smartphone chip. The incorporation of Pixelworks' professional color calibration solution further expands and enhances its color display capabilities. The two companies are engaged in ongoing cooperation to explore more advanced joint solutions at the application systems level.

07:05 EST Advanced Drainage says TXDOT approves thermoplastic pipe for storm sewers - Advanced Drainage Systems announced that the Texas Department of Transportation (TXDOT) released a new special specification that approves the use of thermoplastic pipe in storm sewer and culvert applications statewide.

07:04 EST J.M. Smucker CEO says 'organic top-line growth across all of our businesses' - "Our second quarter results reflect the ongoing strength of our business, continued demand for our leading brands, and the ability of our team to execute with excellence," said Mark Smucker, Chair of the Board, President and CEO. "We delivered organic top-line growth across all of our businesses, driven by the strength of our portfolio, and our ability to recover cost inflation and manage our supply chain environment. Given our strong performance and sustained business momentum, we are raising our net sales and adjusted earnings per share expectations for this fiscal year. Looking ahead, we will continue to execute on our strategy and make investments in our key growth platforms to ensure consistent top- and bottom-line growth, continuing to position us well to deliver long-term shareholder value."

06:47 EST Merck to acquire Imago BioSciences for $36.00 per share in cash, or $1.35B - Merck (MRK) and Imago BioSciences (IMGO) announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35B. Under the terms of the acquisition agreement, Merck, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Imago. The closing of the tender offer will be subject to certain conditions, including the tender of shares representing at least a majority of the total number of Imago's outstanding shares, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. Upon the successful completion of the tender offer, Merck's acquisition subsidiary will be merged into Imago, and any remaining shares of common stock of Imago will be canceled and converted into the right to receive the same $36 per share price payable in the tender offer. The transaction is expected to close in the first quarter of 2023.

06:40 EST NEXT Renewable to go public via merger with Industrial Tech Acquisitions II - NEXT Renewable Fuels and Industrial Tech Acquisitions II announced the signing of a business combination agreement expected to result in a newly combined company to be known as NXTCLEAN Fuels. The boards of directors of NXT and ITAQ have each approved the transaction. The combined company is expected to have an implied post-money pro forma enterprise value of approximately $530M and an equity value of approximately $666M at closing, assuming no redemptions by ITAQ public shareholders. Assuming no redemptions by ITAQ public shareholders, the transaction is expected to deliver up to approximately $176M of cash held in ITAQ's trust account. The conditions to NXT's closing include the amount remaining in the trust account after any redemptions by ITAQ's public stockholders, plus the net proceeds of any private financing completed by ITAQ, is at least $50M. ITAQ has retained England & Company for a private capital raise, if necessary. In the transaction, a newly formed subsidiary of ITAQ will merge with NXT, with NXT surviving as a wholly owned subsidiary of ITAQ. Pursuant to the merger, all pre-closing stockholders and holders of convertible debt of NXT will receive common stock of ITAQ, which will continue after the closing as a publicly traded company under the name NXTCLEAN Fuels, Inc. The transaction, which has been approved by the boards of directors of both NXT and ITAQ, is expected to close late in the second quarter of 2023, subject to shareholder approvals and other customary closing conditions.

06:33 EST Entain awarded five gaming, poker services licenses throughout Germany - Entain announced that it has been awarded licenses by the State Administrative Office of Saxony-Anhalt, for the operation of its gaming and poker services throughout Germany. The Group has been granted all five licenses it applied for, enabling it to offer gaming under its bwin, Ladbrokes and Sportingbet brands, and poker under bwin and Ladbrokes. Each license is granted for a term of five years. Entain is the first operator to be licensed to offer online poker. The new awards are in addition to Entain's existing licenses to offer online sports betting under each brand and will enable the Group to enhance and develop its position as a market leader in sports betting and gaming in Germany.

06:07 EST Apeiron urges Sensei Biotherapeutics board to seek shareholder mandate - Apeiron Investment Group, one of the largest shareholders of Sensei Biotherapeutics, which beneficially owns approximately 11.2% of the outstanding shares of Sensei's stock, announced that it has sent a letter to Sensei's Board of Directors. In the letter, AIG calls for the Board to take immediate action to regain the trust of the shareholders. It suggests the best path forward for Sensei would be to return cash to shareholders. It also encourages all other shareholders to reach out to the Board directly to express their views.

06:01 EST Reviva Pharmaceuticals issued patent covering composition of matter for RP1208 - Reviva Pharmaceuticals announced the issuance of a patent covering composition of matter for RP1208 in Canada, adding to its existing protection in key markets around the world. The Canadian patent covers the compositions of novel phenylcycloalkylmethylamine derivatives and the use of the compositions for the treatment of obesity, and related co-morbid conditions and depression and related co-morbid conditions.

05:36 EST Blackstone commits up to $359M to buy majority stake in R Systems - Blackstone announced last week that private equity funds managed by Blackstone signed definitive agreements with Satinder Singh Rekhi and other current promoters to purchase a majority stake in R Systems International Limited. Satinder Singh Rekhi and the other promoters currently hold ~52% stake in R Systems, which Blackstone will acquire for INR 245 per share. Blackstone will also launch a conditional delisting offer, at a price of INR 246 per share. The transaction is expected to be completed in the coming months, subject to customary closing conditions and regulatory approvals. Rekhi will continue to guide the company in his role as a non-executive advisor. Reference Link

05:27 EST Cellebrite announces closed case with GLAA - Cellebrite announced a closed case with the Gangmasters and Labour Abuse Authority, or GLAA, which brought justice to individuals and businesses that force manual labor. When the agency expanded its mission to cover the entire labor market and strengthened its enforcement powers, a digital forensics lab of their own became a must. To launch their lab, GLAA investigative officers, Richard Shrimpton and Tom Frost, chose Cellebrite mobile forensics collect and review solutions for digital data examination, evidence gathering, and digital data collection. The new digital forensics lab highlighted GLAA's digital transformation in a case that went to court in mid-2022. In 2018, a GLAA investigator received a call from a licensed labor provider concerned about a person working at a factory in Wales. The person, who was from Eastern Europe, told GLAA's southwestern investigators that work was promised in a local bakery, along with suitable housing.

05:20 EST ACI Worldwide, NTT Data to partner to advance Europe and Latin America market - ACI Worldwide and NTT Data will work together to advance growth into new markets across Europe and Latin America, focusing on the Italian market initially. Under a recently signed partnership, NTT DATA will integrate ACI Secure e-commerce into its technology solutions portfolio, instantly expanding merchant access to hundreds of local and cross-border acquirers and new card, digital and mobile payment methods.

04:37 EST Disney names Bob Iger as CEO for two years, Bob Chapek steps down - Disney announced that Robert Iger is returning to lead the company as Chief Executive Officer, effective immediately. Iger, who spent more than four decades at the company, including 15 years as its CEO, has agreed to serve as Disney's CEO for two years, with a mandate from the board to set the strategic direction "for renewed growth and to work closely with the Board in developing a successor to lead the Company at the completion of his term." Iger succeeds Bob Chapek, who has stepped down from his position. The position of Chairman of the Board remains unchanged, with Susan Arnold serving in that capacity.